Grünenthal and Mundipharma enter commercial partnership in China

Aachen(Beijing (ots) - Grünenthal and Mundipharma announced today
that they have entered into a License and Distribution Agreement.
Under its terms, Mundipharma will market and distribute Grünenthal's
Tramal® (tramadol) in China from May 1, 2018.

Developed by Grünenthal, Tramal® is a well-established analgesic
for the treatment of moderate to severe pain. It is the only
international brand of tramadol in China that includes sustained
release tablets and immediate release capsules, as well as an
intravenous formulation used for post-operative pain in patient
controlled intravenous analgesia (PCIA). Delivering the analgesic
intravenously with a patient-controlled device can provide an
important and effective pain control option for patients.[1]

"Poorly controlled post-operative pain may delay the recovery
process, and negatively impact patients' quality of life. With
Tramal®, which has a long track record in the Chinese market, we are
proud to offer a solution that helps patients in need," Gabriel
Baertschi, CEO Grünenthal, explains. "Given Mundipharma's strong
commitment and experience in pain management in China, we hope to
make Tramal® available for even more Chinese pain-patients in need of
effective medication."

"The addition of Tramal® to our portfolio reinforces Mundipharma's
position as the international leader in advancing appropriate
cancer-related pain relief in China," says Raman Singh, CEO
Mundipharma. "PCIA is an advanced option for medical professionals to
treat patients suffering from moderate to severe pain. We are pleased
to extend our relationship with Grünenthal to advance the treatment
of patients in China, where there remains an unmet patient need," he
adds. "Both organisations are committed to ensuring the responsible
use of analgesic medications to treat post-operative patients when
other options provide insufficient relief."

About Grünenthal

The Grünenthal Group is an entrepreneurial, science-based
pharmaceutical company specializing in pain, gout and inflammation.
Our ambition is to deliver four to five new products to patients in
diseases with high unmet medical need by 2022 and become a EUR 2 bn
company. We are a fully integrated research and development company
with a long track record of bringing innovative pain treatments and
state-of-the-art technologies to patients. By sustainably investing
in our R&D above the industrial average, we are strongly committed to
innovation.

Grünenthal is an independent, family-owned company headquartered
in Aachen, Germany. We are present in 32 countries with affiliates in
Europe, Latin America and the US. Our products are sold in more than
155 countries and approx. 5,500 employees are working for the
Grünenthal Group worldwide. In 2016, Grünenthal achieved revenues of
approx. EUR 1.4 bn.

For more information, please visit: www.grunenthal.com

Follow us on LinkedIn "Grunenthal Group".

(R): Tramal is a registered trademark of Grünenthal Group

About Mundipharma

Mundipharma is a network of independent associated companies which
are privately owned entities covering pharmaceutical markets in
Asia-Pacific, Latin America, Middle East and Africa. The headquarters
for these territories is in Singapore. Mundipharma is a prime example
of a company that consistently delivers high quality products while
standing by the values that represent the company. Our mission is to
alleviate the suffering of patients and to substantially improve
their quality of life. Mundipharma is dedicated to bringing to
patients the benefit of novel treatment options in fields such as
pain, oncology, oncology supportive care, ophthalmology, respiratory
disease and consumer healthcare.

For more information, please visit: www.mundipharma.com.cn/

[1: Xiaohui Chi, Man Li, Wei Mei, Mingfeng Liao. Comparison of
patient-controlled intravenous analgesia with sufentanil versus
tramadol in post-cesarean section pain management and lactation after
general anesthesia - a prospective, randomized, double-blind,
controlled study. J Pain Res. 2017; 10: 1521-1527.]

For further information, please contact:
Stepan Kracala, Global Head Corporate Communications
Tel.: +49 241 569-1335, Stepan.Kracala@grunenthal.com
Grünenthal GmbH, 52099 Aachen, Germany

Stephenie Vasko
Head of Communications & Digital Strategy
Asia Pacific, Middle East, Africa & Latin America
+65-6303-9732

Original-Content von: Grünenthal Group, übermittelt durch news aktuell